SciSparc (SPRC) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SciSparc is the larger company by market cap ($481,603 vs $273,955), about 1.8 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -54.6%). SciSparc converts more of its revenue into profit, with a net margin of -481.2% versus -545.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SPRC | SXTC |
|---|---|---|
| Share price | $0.1955 | $2.65 |
| Market cap | $481.60K | $273.95K |
| 1-day change | -34.83% | +2.12% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $248.24 | $-73,040.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.31M | $1.14M |
| Revenue growth (YoY) | -54.64% | -34.63% |
| Net income (latest FY) | $-6.28M | $-6.21M |
| Gross margin | 38.74% | 21.85% |
| Operating margin | -560.18% | -625.89% |
| Net margin | -481.16% | -545.24% |
| 52-week high | $29.88 | $8,376,000.00 |
| 52-week low | $0.167 | $2.52 |
| Distance from 52-week high | -99.35% | -100.00% |
| Average volume | 2.93M | 234.25K |
| Shares outstanding | 2.46M | 103.58K |
| Employees | 3 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SciSparc is more profitable, keeping -481.2 cents of every revenue dollar as net income versus -545.2 cents for China SXT Pharmaceuticals.
- China SXT Pharmaceuticals grew revenue faster in its latest fiscal year (-34.63% vs -54.64%).
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
SPRC vs SXTC FAQ
Which is bigger, SciSparc or China SXT Pharmaceuticals?
SciSparc (SPRC) is larger, with a market capitalization of $481.60K compared with $273.95K for China SXT Pharmaceuticals (SXTC).
Are SciSparc and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.